Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Etretinate: Appropriate Use in Severe Psoriasis

Etretinate: Appropriate Use in Severe Psoriasis Abstract Etretinate is a synthetic retinoid that has been shown to be effective for several types of psoriasis in numerous studies, including severe recalcitrant plaque psoriasis and erythrodermic and generalized pustular psoriasis.1-10 The drug has recently been approved by the Food and Drug administration for these types of psoriasis. We would like to discuss the appropriate use of this drug in severe forms of psoriasis, and to comment on some of the contents of the editorial "Etretinate and Psoriasis" that was authored by Warwick L. Morison, MD, and published in the July 1987 issue of the Archives.11 We feel that the attempts to educate the dermatologist in the selection of patients and use of this agent have been appropriate. It would have been remiss for this agent to have been made available for prescription without a carefully organized educational endeavor to ensure the correct use of this drug. See References 1. Kaplan RP, Russel DH, Lowe NJ: Etretinate therapy for psoriasis: Clinical responses, remission times, epidermal DNA, and polyamine responses . J Am Acad Dermatol 1983;8:95-102.Crossref 2. Orfanos CE: Oral retinoids: Present status . Br J Dermatol 1980;103:473-482.Crossref 3. Moy R, Kingston T, Lowe NJ: Isotretinoin vs etretinate therapy in generalized pustular and chronic psoriasis . Arch Dermatol 1985;121:1297-1301.Crossref 4. Ellis CN, Voorhees JJ: Etretinate therapy . J Am Acad Dermatol 1987;16:267-291.Crossref 5. Lowe NJ, Kaplan R, Breeding J: Etretinate treatment for psoriasis inhibits epidermal ornithine decarboxylase . J Am Acad Dermatol 1982;6:697-698.Crossref 6. Grekin RC, Ellis CN, Goldstein NG, et al: Decreased urinary polyamines in patients with psoriasis treated with etretinate . J Invest Dermatol 1983;80:181-184.Crossref 7. Krueger GG, Shelby NJ, Hansen CD, et al: Clinical labeling indices of skin involved with psoriasis: Placebo and oral retinoid Ro 10-9359 vs time , abstracted. Clin Res 1980;28:21. 8. Fritsch P: Oral retinoids in dermatology . Int J Dermatol 1981;20:314-329.Crossref 9. Runne V, Orfanos CE, Gartmen H: Perorale Applikation drei weir derivate der Vitamin-A-Saure zur internen Psoriasis-Therapie: 13-cis-beta Vitamin-A Saure und Aethylamid . Arch Dermatol Res 1973;247:171-180.Crossref 10. Gollnick H, Orfanos CE: Clinical efficacy of retinoids: European experiences , in Roenigk HH, Maibach HI (eds): Psoriasis . New York, Marcel Dekker, 1985, pp 637-644. 11. Morison WL: Etretinate and psoriasis . Arch Dermatol 1987;123:879-881.Crossref 12. Fritsch PO, Honigsmann H, Jaschkie E, et al: Augmentation of oral methotrexate photochemotherapy with an oral retinoic acid derivative . J Am Acad Dermatol 1978;70:178-182. 13. Heidbreder G, Christophers E: Therapy of psoriasis with retinoid plus PUVA: Clinical and histologic data . Arch Dermatol 1979;264:331-337.Crossref 14. Grupper C, Berretti B: Treatment of psoriasis by oral PUVA therapy combined with aromatic retinoid (Ro 10-9359; Tigason) . Dermatologica 1981;62:404-413.Crossref 15. Christiansen JV, Holm P, Moller R, et al: Etretinate and betamethase valerate in the treatment of psoriasis . Dermatologica 1982;165:204-207.Crossref 16. Orfanos CE, Runne U: Systemic use of a new retinoid with and without local dithranol treatment in generalized psoriasis . Br J Dermatol 1976;95:101-103.Crossref 17. Orfanos CE, Steigleder KG, Pullman H, et al: Oral retinoid and UVB radiation: A new alternative treatment for psoriasis on an outpatient basis . Acta Derm Venereol 1979;59:241-244. 18. Boer J, Suurmond D: Combined UVB phototherapy and low-dosage oral retinoid (Ro 10-9359) for psoriasis responding inadequately to UVB alone , in Orfanos CE, Braun FalcO, Farber EM et al (eds): Retinoids . New York, Springer-Verlag NY Inc, 1981, pp 439-442. 19. Rosen K, Mobacken H, Swanbeck G: PUVA, etretinate, and PUVA-etretinate therapy for pustulosis palmoplantaris: A placebo-controlled comparative trial . Arch Dermatol 1987;123:885-889.Crossref 20. Weiss VC, Layden T, Spanowitz A: Chronic active hepatitis associated with etretinate therapy . Br J Dermatol 1985;112:591-597.Crossref 21. Roenigk HH, Gibstine C, Glazer S, et al: Serial liver biopsies in psoriatic patients receiving long-term etretinate . Br J Dermatol 1985;112:69-76.Crossref 22. Kingston TP, Matt LH, Lowe NJ: Etretin therapy for severe psoriasis . Arch Dermatol 1987;123:55-58.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Dermatology American Medical Association

Etretinate: Appropriate Use in Severe Psoriasis

Archives of Dermatology , Volume 124 (4) – Apr 1, 1988

Loading next page...
 
/lp/american-medical-association/etretinate-appropriate-use-in-severe-psoriasis-ngvzz2Tf2i

References (22)

Publisher
American Medical Association
Copyright
Copyright © 1988 American Medical Association. All Rights Reserved.
ISSN
0003-987X
eISSN
1538-3652
DOI
10.1001/archderm.1988.01670040029016
Publisher site
See Article on Publisher Site

Abstract

Abstract Etretinate is a synthetic retinoid that has been shown to be effective for several types of psoriasis in numerous studies, including severe recalcitrant plaque psoriasis and erythrodermic and generalized pustular psoriasis.1-10 The drug has recently been approved by the Food and Drug administration for these types of psoriasis. We would like to discuss the appropriate use of this drug in severe forms of psoriasis, and to comment on some of the contents of the editorial "Etretinate and Psoriasis" that was authored by Warwick L. Morison, MD, and published in the July 1987 issue of the Archives.11 We feel that the attempts to educate the dermatologist in the selection of patients and use of this agent have been appropriate. It would have been remiss for this agent to have been made available for prescription without a carefully organized educational endeavor to ensure the correct use of this drug. See References 1. Kaplan RP, Russel DH, Lowe NJ: Etretinate therapy for psoriasis: Clinical responses, remission times, epidermal DNA, and polyamine responses . J Am Acad Dermatol 1983;8:95-102.Crossref 2. Orfanos CE: Oral retinoids: Present status . Br J Dermatol 1980;103:473-482.Crossref 3. Moy R, Kingston T, Lowe NJ: Isotretinoin vs etretinate therapy in generalized pustular and chronic psoriasis . Arch Dermatol 1985;121:1297-1301.Crossref 4. Ellis CN, Voorhees JJ: Etretinate therapy . J Am Acad Dermatol 1987;16:267-291.Crossref 5. Lowe NJ, Kaplan R, Breeding J: Etretinate treatment for psoriasis inhibits epidermal ornithine decarboxylase . J Am Acad Dermatol 1982;6:697-698.Crossref 6. Grekin RC, Ellis CN, Goldstein NG, et al: Decreased urinary polyamines in patients with psoriasis treated with etretinate . J Invest Dermatol 1983;80:181-184.Crossref 7. Krueger GG, Shelby NJ, Hansen CD, et al: Clinical labeling indices of skin involved with psoriasis: Placebo and oral retinoid Ro 10-9359 vs time , abstracted. Clin Res 1980;28:21. 8. Fritsch P: Oral retinoids in dermatology . Int J Dermatol 1981;20:314-329.Crossref 9. Runne V, Orfanos CE, Gartmen H: Perorale Applikation drei weir derivate der Vitamin-A-Saure zur internen Psoriasis-Therapie: 13-cis-beta Vitamin-A Saure und Aethylamid . Arch Dermatol Res 1973;247:171-180.Crossref 10. Gollnick H, Orfanos CE: Clinical efficacy of retinoids: European experiences , in Roenigk HH, Maibach HI (eds): Psoriasis . New York, Marcel Dekker, 1985, pp 637-644. 11. Morison WL: Etretinate and psoriasis . Arch Dermatol 1987;123:879-881.Crossref 12. Fritsch PO, Honigsmann H, Jaschkie E, et al: Augmentation of oral methotrexate photochemotherapy with an oral retinoic acid derivative . J Am Acad Dermatol 1978;70:178-182. 13. Heidbreder G, Christophers E: Therapy of psoriasis with retinoid plus PUVA: Clinical and histologic data . Arch Dermatol 1979;264:331-337.Crossref 14. Grupper C, Berretti B: Treatment of psoriasis by oral PUVA therapy combined with aromatic retinoid (Ro 10-9359; Tigason) . Dermatologica 1981;62:404-413.Crossref 15. Christiansen JV, Holm P, Moller R, et al: Etretinate and betamethase valerate in the treatment of psoriasis . Dermatologica 1982;165:204-207.Crossref 16. Orfanos CE, Runne U: Systemic use of a new retinoid with and without local dithranol treatment in generalized psoriasis . Br J Dermatol 1976;95:101-103.Crossref 17. Orfanos CE, Steigleder KG, Pullman H, et al: Oral retinoid and UVB radiation: A new alternative treatment for psoriasis on an outpatient basis . Acta Derm Venereol 1979;59:241-244. 18. Boer J, Suurmond D: Combined UVB phototherapy and low-dosage oral retinoid (Ro 10-9359) for psoriasis responding inadequately to UVB alone , in Orfanos CE, Braun FalcO, Farber EM et al (eds): Retinoids . New York, Springer-Verlag NY Inc, 1981, pp 439-442. 19. Rosen K, Mobacken H, Swanbeck G: PUVA, etretinate, and PUVA-etretinate therapy for pustulosis palmoplantaris: A placebo-controlled comparative trial . Arch Dermatol 1987;123:885-889.Crossref 20. Weiss VC, Layden T, Spanowitz A: Chronic active hepatitis associated with etretinate therapy . Br J Dermatol 1985;112:591-597.Crossref 21. Roenigk HH, Gibstine C, Glazer S, et al: Serial liver biopsies in psoriatic patients receiving long-term etretinate . Br J Dermatol 1985;112:69-76.Crossref 22. Kingston TP, Matt LH, Lowe NJ: Etretin therapy for severe psoriasis . Arch Dermatol 1987;123:55-58.Crossref

Journal

Archives of DermatologyAmerican Medical Association

Published: Apr 1, 1988

There are no references for this article.